Opendata, web and dolomites

ZIKAVAX SIGNED

Fast track development of a Zika vaccine based on measles vector

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ZIKAVAX project word cloud

Explore the words cloud of the ZIKAVAX project. It provides you a very rough idea of what is the project "ZIKAVAX" about.

disease    pathogens    effectiveness    innovative    track    infectious    emergency    volunteers    unaffected    infection    themis    ia    preclinical    atomique    platform    safe    declared    agrave    ultimate    nor    committed    bioscience    adaptability    manufacturing    therapies    health    diseases    energie    previously    organization    virus    adult    human    affordable    borne    demonstration    brain    complications    1947    regions    date    pasteur    adults    antigen    primates    flavivirus    purity    give    humans    model    immunisation    rapid    spread    candidate    variety    commissariat    immunogenicity    outbreak    standard    public    mice    zika    recombinant    expression    severe    truly    isolated    trial    safety    vaccine    mosquito    vaccines    yield    borns    vector    neurological    consequently    epidemiological    world    zikavax    record    institut    preventive    urgent    issue    proof    measles    malformations    clinical    demonstrated    congenital    treatments   

Project "ZIKAVAX" data sheet

The following table provides information about the project.

Coordinator
EUROPEAN VACCINE INITIATIVE EWIV 

Organization address
address: VOSSSTRASSE 2 GEB 4040
city: HEIDELBERG
postcode: 69115
website: http://www.euvaccine.eu/

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Project website http://www.zikavax.eu
 Total cost 4˙918˙137 €
 EC max contribution 4˙918˙137 € (100%)
 Programme 1. H2020-EU.3.1.2. (Preventing disease)
 Code Call H2020-SC1-2016-RTD
 Funding Scheme RIA
 Starting year 2016
 Duration (year-month-day) from 2016-10-01   to  2020-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    EUROPEAN VACCINE INITIATIVE EWIV DE (HEIDELBERG) coordinator 673˙968.00
2    THEMIS BIOSCIENCE GMBH AT (WIEN) participant 3˙192˙862.00
3    INSTITUT PASTEUR FR (PARIS CEDEX 15) participant 562˙290.00
4    COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES FR (PARIS 15) participant 489˙016.00

Map

 Project objective

Zika virus is an emerging mosquito-borne flavivirus. Although already isolated in 1947, to date there are no specific treatments nor any vaccines available against Zika virus disease, making it a truly neglected infectious disease. The recent rapid spread of the Zika virus in previously unaffected regions has provided strong epidemiological evidence that infection with this virus might be associated with neurological complications in adults and with an increase in severe congenital brain malformations of new-borns. Consequently, the World Health Organization has declared the recent outbreak of the Zika virus a public health emergency. The ZIKAVAX proposal has the objective to address this urgent public health issue by promoting the rapid development of a safe, effective, and affordable preventive vaccine against Zika virus infection. To achieve this goal, ZIKAVAX will use a delivery platform technology based on a measles vaccine vector with demonstrated proof of principle in humans and a preclinical track record of rapid adaptability and effectiveness for a variety of pathogens. The manufacturing process for these measles vector-based vaccines has been developed to give high yield and purity using standard equipment. In ZIKAVAX, following antigen selection and expression, immunisation studies will be conducted with the Zika vaccine candidate in mice and in a challenge model in non-human primates that will developed by the consortium. The ultimate goal of ZIKAVAX is the demonstration of safety and immunogenicity of a recombinant measles-Zika vaccine candidate in adult volunteers in a phase Ia clinical trial. ZIKAVAX is driven by a strongly committed and effective consortium of four leading European organisations highly experienced in vaccine research and development. Its partners include the European Vaccine Initiative, Institut Pasteur, Themis Bioscience GmbH and the Institute of Emerging Diseases and Innovative Therapies from the Commissariat à l’Energie Atomique.

 Deliverables

List of deliverables.
Launch of the website Websites, patent fillings, videos etc. 2019-05-30 15:16:10

Take a look to the deliverables list in detail:  detailed list of ZIKAVAX deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ZIKAVAX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ZIKAVAX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.2.)

ECRC (2019)

Developing a diverse portfolio of vaccine candidates for Rift Valley Fever, Chikungunya and Ebola

Read More  

EMPOWER (2020)

European platforM to PromOte Wellbeing and HEalth in the woRkplace

Read More  

RISCC (2020)

RISK-BASED SCREENING FOR CERVICAL CANCER

Read More